News for MoonLake Immunotherapeutics Stock (MLTX)

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

GlobeNewsWire • 04/10/24

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Business Wire • 04/10/24

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Investors Business Daily • 03/11/24

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewsWire • 03/10/24

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewsWire • 03/04/24

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

GlobeNewsWire • 02/29/24

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewsWire • 02/26/24

The 7 Best Momentum Stocks You Can Purchase Today

InvestorPlace • 02/12/24

Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade

Zacks Investment Research • 01/11/24

Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

Zacks Investment Research • 01/10/24

MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment

Seeking Alpha • 12/09/23

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 11/14/23

MoonLake Immunotherapeutics stock craters after arthritis treatment study disappoints

Proactive Investors • 11/06/23

Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug

Investors Business Daily • 11/06/23

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

GlobeNewsWire • 11/05/23

Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout

Investors Business Daily • 10/16/23

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

GlobeNewsWire • 10/15/23

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

GlobeNewsWire • 10/11/23

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

GlobeNewsWire • 10/04/23

7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio

InvestorPlace • 09/28/23

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Seeking Alpha • 09/28/23

These 8 Stocks Are Outperforming Nvidia In 2023

Investors Business Daily • 09/18/23

Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

The Motley Fool • 09/12/23

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 13%

Investors Business Daily • 09/12/23

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

GlobeNewsWire • 09/06/23